Biocon Ltd 2021 SR
The report highlights Biocon's commitment to unconditional equity across health, people, and the environment during fiscal year 2021. Key achievements include reaching 3.1 million patients with biosimilars and supplying 2.75 billion doses of rh-Insulin since 2004. The company achieved an 18% reduction in absolute Scope 1 and Scope 2 emissions compared to the FY20 baseline and sourced 53% of its electricity from green power. Biocon also emphasized its diversity goals, aiming for a 50:50 gender ratio by 2030, and detailed its extensive COVID-19 relief efforts, including the repurposing of Itolizumab.
Company: Biocon Ltd
Sector: Manufacturing
Country: India
Year: 2021
Type: SR
Pages: 36
Back to company
Biocon Ltd
ESG Summary Report
The report highlights Biocon's commitment to unconditional equity across health, people, and the environment during fiscal year 2021. Key achievements include reaching 3.1 million patients with biosimilars and supplying 2.75 billion doses of rh-Insulin since 2004. The company achieved an 18% reduction in absolute Scope 1 and Scope 2 emissions compared to the FY20 baseline and sourced 53% of its electricity from green power. Biocon also emphasized its diversity goals, aiming for a 50:50 gender ratio by 2030, and detailed its extensive COVID-19 relief efforts, including the repurposing of Itolizumab.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Published
Jun 18, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees